RXRX icon

Recursion Pharmaceuticals

5.54 USD
+0.61
12.37%
Updated Jul 8, 10:37 AM EDT
1 day
12.37%
5 days
10.80%
1 month
3.17%
3 months
39.55%
6 months
-23.69%
Year to date
-23.16%
1 year
-25.14%
5 years
-82.30%
10 years
-82.30%
 

About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Employees: 800

0
Funds holding %
of 7,311 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

106% more repeat investments, than reductions

Existing positions increased: 138 | Existing positions reduced: 67

61% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 41

30% more call options, than puts

Call options by funds: $28.3M | Put options by funds: $21.7M

7% more funds holding

Funds holding: 312 [Q4 2024] → 333 (+21) [Q1 2025]

2.41% less ownership

Funds ownership: 79.42% [Q4 2024] → 77.01% (-2.41%) [Q1 2025]

10% less funds holding in top 10

Funds holding in top 10: 10 [Q4 2024] → 9 (-1) [Q1 2025]

22% less capital invested

Capital invested by funds: $2.06B [Q4 2024] → $1.61B (-$451M) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$5
10%
downside
Avg. target
$6.50
17%
upside
High target
$8
44%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Morgan Stanley
Vikram Purohit
10%downside
$5
Equal-Weight
Assumed
3 Jul 2025
Needham
Gil Blum
44%upside
$8
Buy
Maintained
6 May 2025

Financial journalist opinion

Based on 10 articles about RXRX published over the past 30 days

Neutral
Forbes
3 hours ago
What's Happening With RXRX Stock?
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach to drug discovery driven by AI and machine learning.
What's Happening With RXRX Stock?
Negative
The Motley Fool
4 hours ago
The Hottest 10 Artificial Intelligence (AI) Stocks on the Market
There's little doubt that artificial intelligence is here to stay. It's just too game-changing to put back in the box now.
The Hottest 10 Artificial Intelligence (AI) Stocks on the Market
Positive
Zacks Investment Research
23 hours ago
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
Positive
Zacks Investment Research
4 days ago
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.27, denoting a +1.15% move from the preceding trading day.
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
Positive
Zacks Investment Research
5 days ago
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Neutral
Zacks Investment Research
1 week ago
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Recursion Pharmaceuticals (RXRX) reached $5.03 at the closing of the latest trading day, reflecting a -6.85% change compared to its last close.
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Neutral
Zacks Investment Research
2 weeks ago
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $5.03, representing a -1.57% change from its previous close.
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
Positive
The Motley Fool
3 weeks ago
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?
Recursion Pharmaceuticals (RXRX -5.13%) is not the most famous artificial intelligence (AI) stock on the market, but the biotech (or techbio) company has attracted the attention of some big names. Recursion has partnered with the AI juggernaut Nvidia to build a powerful supercomputer, for example.
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?
Positive
The Motley Fool
3 weeks ago
Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday
In an effort to save costs and make its financial resources last longer, Recursion Pharmaceuticals (RXRX 1.49%) is slimming down and streamlining. After the biotech updated its strategy to do so on Tuesday, investors became more hopeful on its future, bidding the stock up; it closed 1.6% higher at the end of the day.
Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday
Negative
Reuters
4 weeks ago
Recursion to lay off 20% of workforce, narrows focus amid biotech downturn
Recursion Pharmaceuticals said on Tuesday it will lay off around 20% of its workforce and focus on developing drugs for rare diseases and cancers to reduce cash burn during a prolonged biotech industry downturn.
Recursion to lay off 20% of workforce, narrows focus amid biotech downturn
Charts implemented using Lightweight Charts™